The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.

The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...

The firm said a pivotal Phase III study, testing daraxonrasib as a second-line treatment for RAS-mutant pancreatic cancer, will yield results in the first half of 2026.

NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).

The company highlighted multiple myeloma and CAR T therapies as growth drivers and announced two new US manufacturing ...

Since its US, Japan, and China approvals, the ROS1-positive NSCLC drug recorded $15.7 million and $24.7 million in revenue in Q4 and full-year 2025, respectively.

The company plans to begin a registrational trial of a GPC3-targeted cell therapy for hepatocellular carcinoma.

The agency is asking the firm to conduct a new study, which Pierre Fabre says is "a significant and unexpected change" from prior discussions.

The firm is continuing a Phase I study of its lead SMARCA4 inhibitor and will advance its CBP and selective EP300 degrader programs into the clinic in 2026.

The firm expects its $1.25 billion cash runway to cover operating and capital expenses through 2029, including development plans for key assets.

The agency outlined the adjustments it's willing to make to "remove barriers and perceived misconceptions" for innovative medicines.